Detection of Varicella Zoster Virus Reactivation in Cerebrospinal Fluid in Ischemic Stroke or Transient Ischemic Attack

 Varicella-zoster virus (VZV) is a type of herpes virus that causes chickenpox, shingles and other infections. The virus stays in your body and can reactivate years later. VZV infections can cause a painful or itchy rash, fever and other symptoms, depending on where you’re infected. Getting vaccinated can prevent varicella-zoster infections.

Which is why I got the updated shingles vaccine.

• shingles (29 posts to August 2016) 

Detection of Varicella Zoster Virus Reactivation in Cerebrospinal Fluid in Ischemic Stroke or Transient Ischemic Attack

Wenyang Li, MD https://orcid.org/0000-0002-2655-7144, Peter Sguigna, MD https://orcid.org/0000-0003-1825-575X, Chintan Rupareliya, MD, MPH https://orcid.org/0000-0002-9475-094X, Suriya Subramanian, MD https://orcid.org/0009-0003-8652-4998, Hisham Salahuddin, MD, MPH, Khalil S. Husari, MD, William Moore, MD, Mark Johnson, MD https://orcid.org/0000-0002-1625-6997, Alejandro Magadan, MD, Charles Grose, MD https://orcid.org/0000-0001-6884-6668, Ank E. Nijhawan, MD, MPH https://orcid.org/0000-0003-0522-4110, and Ty Shang, MD, PhD https://orcid.org/0000-0001-5102-4641 ty.shang@utsouthwestern.eduAuthor Info & Affiliations

Journal of the American Heart Association

New online

https://doi.org/10.1161/JAHA.124.039489

Track Citations Add to favorites

• Information & Authors
• Metrics & Citations
• View Options
• References
• Figures
• Tables
• Media
• Share

Abstract

Background

Epidemiological data suggest that the risk of ischemic stroke increases after varicella‐zoster virus (VZV) reactivation. The frequency of VZV reactivation in acute ischemic stroke (AIS) is unknown. The risk of recurrent stroke and the antiviral treatment effect, particularly in patients with HIV infection, have yet to be defined. Here, we investigate the proportion of VZV reactivation in the cerebrospinal fluid (CSF) of patients who presented with AIS or transient ischemic attack and underwent VZV testing, along with relevant follow‐up information.

Methods

We retrospectively reviewed medical records of patients who presented with AIS or transient ischemic attack and underwent VZV polymerase chain reaction and anti‐VZV IgG testing in CSF during their workup from January 1, 2014, to December 31, 2021. VZV reactivation was confirmed by a positive VZV polymerase chain reaction result or increased intrathecal anti‐VZV IgG synthesis in CSF. The cause of AIS and transient ischemic attack was classified using the SSS‐TOAST (Stop Stroke Study‐Trial of ORG 10172 in Acute Stroke Treatment) criteria. The occurrence of recurrent ischemic stroke during follow‐up was compared between patients who received antiviral treatment and those who did not, as well as between patients with and without HIV.

Results

Among the 177 patients included, VZV reactivation in CSF was found in 23.2%. VZV reactivation was more common in strokes involving intracranial arteries compared with those that did not (28% versus 3%, P=0.01). Seven (17%) patients with VZV reactivation had recurrent ischemic stroke within 1 year from positive test results. There was no significant difference in recurrent ischemic stroke between patients who received short‐term antiviral therapy and those who did not (14.8% versus 21%, P=0.593). Patients with AIS and HIV had a significantly higher risk of VZV reactivation (57% versus 20%, P=0.002) and recurrent ischemic stroke despite antiviral treatment (42.8% versus 5.0%, P=0.02) compared with patients without HIV.

Conclusions

Among individuals who underwent VZV testing in CSF, VZV reactivation was present in 1 of 5 patients with AIS/transient ischemic attack. Patients with HIV were at particularly high risk of VZV reactivation and recurrent ischemic stroke.